http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-200501366-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 |
| filingDate | 2004-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-200501366-A1 |
| titleOfInvention | MEDICINE |
| abstract | The presented invention relates to a medicinal product comprising an active substance and targeted supplements, moreover it contains (2,4-dihydroxy-6-methyl-5-pyrimidyl) - (4-pyridinecarbonylhydrazinyl) sulfone of formula (III) or its pharmaceutically acceptable salts and isomers in an effective amount. In addition, the proposed drug may additionally contain at least one anti-tuberculosis agent, such as isoniazid, refampicin, pyrazinamide. The proposed drug can be manufactured in the form of tablets, combined tablets, capsules, syrup and injections. |
| priorityDate | 2004-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.